Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details) $ in Thousands		12 Months Ended
	Sep. 26, 2019 USD ($) item	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Agreements
Payments of consideration under RPAs, AAAs and CPPAs		$ 8,000	$ 53,000
Long-term royalty and commercial payment receivables under the cost recovery method		55,888	55,936
Short-term royalty and commercial payment receivables under the cost recovery method		0	413
Palobiofarma | Royalty Purchase Agreement
Agreements
Number of drug candidates | item	6
Payments of consideration under RPAs, AAAs and CPPAs	$ 10,000
Long-term royalty and commercial payment receivables under the cost recovery method	$ 10,000
Short-term royalty and commercial payment receivables under the cost recovery method		0
Allowance for credit losses		$ 0	$ 0